Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36265502

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Nov
First author
Long GV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Jan;24(1):e7. doi: 10.1016/S1470-2045(22)00703-3.
    note
    Source null
    related pmid
    36603930
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2023 Jan;24(1):e8. doi: 10.1016/S1470-2045(22)00753-7.
    note
    Source null
    related pmid
    36603931
    relationship
    Comment in
  3. citation
    Ann Transl Med. 2023 Aug 30;11(10):368. doi: 10.21037/atm-23-839.
    note
    Source null
    related pmid
    37675306
    relationship
    Comment in

Authors and identifiers

  1. name
    Long GV
    type
    Author
  2. name
    Luke JJ
    type
    Author
  3. name
    Khattak MA
    type
    Author
  4. name
    de la Cruz Merino L
    type
    Author
  5. name
    Del Vecchio M
    type
    Author
  6. name
    Rutkowski P
    type
    Author
  7. name
    Spagnolo F
    type
    Author
  8. name
    Mackiewicz J
    type
    Author
  9. name
    Chiarion-Sileni V
    type
    Author
  10. name
    Kirkwood JM
    type
    Author
  11. name
    Robert C
    type
    Author
  12. name
    Grob JJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Long GV
    type
    Author
  2. name
    Luke JJ
    type
    Author
  3. name
    Khattak MA
    type
    Author
  4. name
    de la Cruz Merino L
    type
    Author
  5. name
    Del Vecchio M
    type
    Author
  6. name
    Rutkowski P
    type
    Author
  7. name
    Spagnolo F
    type
    Author
  8. name
    Mackiewicz J
    type
    Author
  9. name
    Chiarion-Sileni V
    type
    Author
  10. name
    Kirkwood JM
    type
    Author
  11. name
    Robert C
    type
    Author
  12. name
    Grob JJ
    type
    Author
bibliography ids
  1. nci-bib-a47e6135890d4dbdcc3fa0fe
book metadata
content sha256
87a6ec699e53a277a16a753d99d748ed3f3b9b614f222fa3b796f9959430c010
document type
citation
dois
  1. 10.1016/S1470-2045(22)00559-9
electronic publication date
display
2022 Oct 18
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36265502
immutable id
pubmed:36265502@87a6ec699e53a277a16a753d99d748ed3f3b9b614f222fa3b796f9959430c010
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1378-1388
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Jan;24(1):e7. doi: 10.1016/S1470-2045(22)00703-3.
    note
    Source null
    related pmid
    36603930
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2023 Jan;24(1):e8. doi: 10.1016/S1470-2045(22)00753-7.
    note
    Source null
    related pmid
    36603931
    relationship
    Comment in
  3. citation
    Ann Transl Med. 2023 Aug 30;11(10):368. doi: 10.21037/atm-23-839.
    note
    Source null
    related pmid
    37675306
    relationship
    Comment in
outcomes validated
false
pmid
36265502
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
653930fcfc09730ec331d88a4a963ade483d7bc806a1fa78147496def9d3af35
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2022 Nov
precision
month
year
2022
publication types
  1. Randomized Controlled Trial
  2. Multicenter Study
  3. Clinical Trial, Phase III
  4. Journal Article
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36265502/
title
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.

Preserved source evidence · Not medical advice